Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Dexcom (DXCM) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Dexcom (DXCM) over the last 17 years, with Q4 2025 value amounting to $469.7 million.

  • Dexcom's Operating Expenses rose 59.97% to $469.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.9 billion, marking a year-over-year increase of 282.34%. This contributed to the annual value of $1.9 billion for FY2025, which is 282.34% up from last year.
  • Per Dexcom's latest filing, its Operating Expenses stood at $469.7 million for Q4 2025, which was up 59.97% from $488.9 million recorded in Q3 2025.
  • Dexcom's 5-year Operating Expenses high stood at $488.9 million for Q3 2025, and its period low was $298.0 million during Q1 2021.
  • Over the past 5 years, Dexcom's median Operating Expenses value was $429.0 million (recorded in 2023), while the average stood at $416.3 million.
  • As far as peak fluctuations go, Dexcom's Operating Expenses skyrocketed by 5994.58% in 2021, and later tumbled by 1188.56% in 2022.
  • Quarter analysis of 5 years shows Dexcom's Operating Expenses stood at $472.0 million in 2021, then dropped by 11.89% to $415.9 million in 2022, then rose by 5.72% to $439.7 million in 2023, then increased by 6.19% to $466.9 million in 2024, then increased by 0.6% to $469.7 million in 2025.
  • Its last three reported values are $469.7 million in Q4 2025, $488.9 million for Q3 2025, and $476.2 million during Q2 2025.